Loading the session
Loading the session
Loading instrument
$10.45
+4.50%Market closedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +2.0% (SPY −1.6%, XLV +13.5%). 3 months: +24.8% (SPY −0.4%, XLV +15.5%). 1 year: +166.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ABSI, SPY and XLV · as of 4 Nov 2026
37.0M shares were sold short at the 15 Oct 2026 settlement, 21.6% of the 171.6M shares outstanding; covering them would take 9.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $10.48 was 9.7% above its 50-day average ($9.55) and 58.9% above its 200-day average ($6.60). It has closed above the 200-day for 143 sessions, since 14 Apr 2026. The 50-day average crossed above the 200-day on 5 May 2026, 127 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $10.48 on 4 Nov 2026: 16.5% below the 52-week high of $12.54 (29 Oct 2026) and 367.9% above the low of $2.24 (12 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
June 24, 2026
+35.96%October 15, 2025
+28.21%May 22, 2023
+30.22%